Business Context and Reporting Period
Company: Village Farms International, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2020
Reporting Period: The filing reports on a specific event occurring on March 19, 2020, regarding a new equity offering. It incorporates by reference financial data from the three and nine months ended September 30, 2019.
Key Financial Metrics and Transaction Details
This filing details a private placement equity offering rather than standard operational financial results. Key transaction metrics include:
- Offering Size: 3,125,000 common shares.
- Issue Price: $3.20 per share (Canadian dollars).
- Gross Proceeds: $10,000,000 (Canadian dollars).
- Over-Allotment Option: Underwriter granted an option to purchase up to 15% additional shares at the issue price within 30 days of closing.
- Expected Closing: On or about March 26, 2020.
Note: This filing does not provide current revenue, profit, cash flow, or debt figures. Operational financial data is referenced only via incorporation of prior period statements (Q3 2019).
Material Changes Versus Prior Period
The primary material change reported is the entry into a definitive underwriting agreement for a new equity offering. The filing references a prior material change report dated March 12, 2020, regarding a settlement agreement with Emerald Health Therapeutics, Inc., but does not detail the financial impact of that settlement within this specific text.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the offering to raise capital. The transaction is subject to the completion of formal documentation and receipt of necessary regulatory and stock exchange approvals.
Risks and Contingencies: The closing of the offering is contingent upon regulatory and stock exchange approvals. The Underwriting Agreement includes customary representations, warranties, indemnification obligations, and termination provisions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected March 26, 2020) and whether the over-allotment option was exercised.
- Review the incorporated Q3 2019 Financial Statements (Exhibit 99.2) for the most recent operational performance data.
- Examine the Material Change Report dated March 12, 2020 (Exhibit 99.5) for details on the settlement with Emerald Health Therapeutics, Inc.
- Confirm the use of proceeds from the $10 million offering as disclosed in the full prospectus supplement.